drugset / Trial / NCT06940830

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

NCT06940830

Phase 4 Recruiting 250 enrolled Swedish Orphan Biovitrum PSI CRO · collab
NaSingle-groupOpen-labelTreatment

Summary

The rationale for this study is to further understand and describe the long-term prophylactic effectiveness of efanesoctocog alfa in preventing joint bleeds in a real-life setting.

Timeline

Start
2025-05-21
Primary completion
2028-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Efanesoctocog alfa Protein / enzyme biologic

Indications